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Figure: Cumulative incidence of major adverse cardiovascular events in the two
study groups.
Conclusion: Glycemic control, determined by HbA1c, does not seem to influence 12-
month cardiovascular outcomes in DM with AMI after successful PCI.
TCT-85
Three-Year Cardiovascular Event Rates Were Lower in Type 2 Diabetic
Patients with Pioglitazone Treatment after Zotarolimus-Eluting Stent
Implantation
Soon Jun Hong, Je Sang Kim, Jae Hyoung Park, Chul-Min Ahn, Do-Sun Lim
Korea University Anam Hospital, Seoul, Republic of Korea
Background: We prospectively investigated the effects of pioglitazone in reducing
MACEs after zotarolimus-eluting stent (ZES) implantation in type 2 diabetic patients
with significant coronary artery narrowing during the 3-year follow-up.
Methods: Type 2 diabetic patients with coronary artery diseases were randomly
assigned to pioglitazone (n=91) or placebo (n=114) after ZES implantation. Primary
endpoint was to compare MACEs such as non-fatal myocardial infarction, death,
stroke, and target lesion revascularization (TLR) between the 2 groups during the 3-
year follow-up. Secondary endpoints were to compare rates of new-onset heart failure,
fracture, and non-TLR target vessel revascularization (TVR) between the 2 groups.
Results: MACEs were significantly higher in the placebo group than the pioglitazone
group during the follow-up [hazard ratio 2.326 (95% CI 1.167-4.638), p=0.016] (Figure
1). Rates of non-fatal myocardial infarction [odds ratio (OR) 1.011 (95% CI 0.989-
1.033)], death [OR 0.974 (95% CI 0.945-1.004)], and stroke [OR 2.537 (95% CI
0.227-28.456)] showed no significant differences between the 2 groups; however, TLR
[OR 0.322 (95% CI 0.144-0.721)] was significantly lower in the pioglitazone group
than the placebo group. Rates of new-onset heart failure [OR 2.222 (95% CI 0.776-
6.365)], fracture [OR 1.636 (95% CI 0.618-4.331)] and non-TLR TVR [OR 1.261
(95% CI 0.248-6.403)] revealed no significant differences between the 2 groups.
Conclusion: Rates of MACEs were significantly lower in the pioglitazone group when
compared with the placebo group, mainly due to the lower rate of TLR during the 3-
year follow-up.
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Similar Target Lesion Revascularization In Non-insulin Dependent Diabetic
Compared with Non-diabetic Patients After Bare Metal Stenting In Lesions
Carrying a Low Risk Of Restenosis
Pier Woudstra, Peter Damman, Marcel Beijk, Maik J Grundeken, Ralf E Harskamp,
Karel T Koch, José P Henriques, Jan Baan, Marije M Vis, Jan J Piek, Jan G Tijssen,
Robbert J de Winter
Department of Cardiology, Academic Medical Center, University of Amsterdam,
Amsterdam, Netherlands
Background: International guidelines recommend the use of drug eluting stents in all
diabetics, regardless of other restenosis risk factors. However, bare metal stents (BMS)
are generally a safe and effective treatment option for low risk of restenosis lesions
(LR lesions). Hence, we analyzed results of diabetics undergoing percutaneous
coronary intervention (PCI) for LR lesions treated with BMS.
Methods: The study population is a single center prospective cohort that underwent
non-urgent PCI between 2003 and 2007. LR lesions were defined as a reference vessel
diameter≥3.0 mm and lesion length≤15 mm. All cardiac events were collected up to 1
year of follow-up. Patients treated with BMS were stratified as no(noDM), non-insulin
requiring (NIRDM) and insulin requiring (IRDM) diabetics. Cumulative event rates
were estimated with the Kaplan-Meier method and compared with a log-rank test.
Results: We included a total of 1951 patients; 1596 noDM, 231 NIRDM, and 124
IRDM. Target lesion revascularization (TLR) rates in non-DM versus NIRDM were
similar (6.3% vs. 5.6%; p=0.68), while TLR in IRDM was higher (6.3% vs. 14.4%;
p=0.03) (Figure). The composite of cardiac death, myocardial infarction and target
vessel revascularization was not significantly different in non-DM versus NIRDM
(9.5% vs. 13.4%; p=0.07), though in IRDM it was higher (9.5% vs. 17.7; P<0.01).
Conclusion: The results implicate that BMS placement may be considered in patients
with NIRDM and LR lesions. Further work is required to define treatment strategies
and, more importantly, improve the outcomes in diabetics.
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Urine NGAL and IL-18 Identify CI-AKI Early in Patients with DM and CKD
Undergoing Coronary Angiography/PCI
Ayesha Catherine Qureshi1, 2, Rajiv Rampat1, Steven Harwood2, Michael Roughton3,
Magdi M Yaqoob1, 2, Akhil Kapur1, 2
1Cardiology, The London Chest Hospital, London, United Kingdom; 2The William
Harvey Research Institute, London, United Kingdom; 3The Royal College of
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Background: The incidence of contrast induced acute kidney injury (CI-AKI)
following coronary angiography/PCI in patients with DM may be up to 30% and is
associated with increased long term morbidity/mortality. Patients with CKD are
excluded from the majority of cardiology trials and are at high risk for development
of CI-AKI. We aimed to identify whether a panel of novel biomarkers could predict
CI-AKI early post procedure allowing earlier identification of affected patients. We
also assessed severity of CAD and whether this influenced the development of CI-
AKI.
Methods: We recruited 208 consecutive patients undergoing elective/urgent coronary
angiography/PCI with known DM and CKD (eGFR <60ml/min). CI-AKI was defined
as a rise in creatinine at day 3 of >25% from baseline or an absolute rise of 44.5μmol/l.
Severity of CAD was assessed by the SYNTAX Score and risk of CI-AKI using the
Mehran score. We evaluated serum and urine NGAL and Il-18 and albuminuria for
additional information about CI-AKI risk. NAC and iv hydration were given to all
patients with eGFR <50 ml/min in accordance with local guidelines.
Results: 116 patients underwent coronary angiography and 92 PCI. 39 patients (18.8%)
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developed CI-AKI. The SYNTAX score did not differ between those who did or did
not develop CI-AKI (p=0.188). The mean Mehran score was significantly higher in
the CI-AKI arm (13.7 vs 11.1 p<0.001) and gave an AUC on ROC analysis of 0.69
(95%CI 0.6-0.78). A 20% increase in urine IL-18 and NGAL at 2 h increased the AUC
to 0.78. Neither albumin:creat ratio (p=0.149) or protein:creat ratio (p=0.635) predicted
development of CI-AKI.
Conclusion: The current gold standard for measuring CI-AKI is a rise in serum
creatinine but this is of limited value as it does not increase until 48-72 hours post renal
injury. Neither the SYNTAX score, nor urinary albuminuria or proteinuria are
predictive of CIN development. A 20% rise in urine NGAL and Il-18 within 2 h of
procedure allows earlier diagnosis of CI-AKI and improves the diagnostic ability of a
well validated risk score for both clinical and investigational purposes.
TCT-88
Twice Daily Dosing of Aspirin is Biologically More Effective in Patients with
Type 2 Diabetes Mellitus and Coronary Artery Disease
Jean-Guillaume Dillinger, Akram Drissa, Georgios Sideris, Claire Bal-dit-Solier,
Sebastian Voicu, Damein Logeart, Ludovic Drouet, Patrick Henry
Cardiology, Lariboisiere Hospital, Paris, France
Background: The efficacy of aspirin in preventing cardiovascular events appears to
be lower in DM patients than in general population. We have previously demonstrated
a time-dependent aspirin efficacy suggesting that once daily aspirin does not provide
24h stable biological efficacy, mainly in patients with DM, inflammatory markers and
active smokers. The objective of the study was to compare biological efficacy of 150
mg/day aspirin given once daily (OPD) as compared to 150mg/day divided in 75 mg
in the morning and 75 mg in the evening (BID) in a cross over study in patients with
DM.
Methods: A randomized monocentric prospective study with cross over is realized in
92 patients with DM and previous acute coronary syndrome with high risk of biological
aspirin resistance (elevated hsCRP, elevated fibrinogen or current smoking). Primary
endpoint is the percentage of aspirin resistant patients measured by light transmission
aggregometry using arachidonic acid 0.5mg/mL (LTA-AA). PFA-100 testing, using
epinephrine cartridges is also performed. Patients are considered resistant if
aggregation is ≥20% with LTA-AA or if PFA-100 epinephrine closure time was ≤193
seconds.
Results: Mean HbA1c is 7.4%±1.2% and 43% of patients are treated with insulin.
Mean age is 64±10 y.o., 85% are male, 34% are active smokers and 52% are treated
with clopidogrel. There is no difference in mean platelet count (270±78G/L), fibrinogen
(3.6±1.0g/L) and hsCRP (5.5±6.9mg/L). Using LTA-AA, mean residual aggregation
was 19.7±15.4% on OPD versus 11.9±10.4% on BID (p<0.001). Biological aspirin
resistance (residual aggregation ≥ 20%) significantly decrease from 42% on OPD to
17% on BID corresponding to a decrease of 62% (p=0.0005). Based on PFA-100, 41%
of patients were resistant on OPD versus 29% on BID (p=0.12). Similar results are
found in patients with or without clopidogrel.
Conclusion: In diabetic patients with elevated inflammatory markers or active
smoking, the same dose of aspirin BID is biologically more effective than OPD.
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AMI Trial
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Background: The association between admission hyperglycemia and mortality in pts
with ST-segment elevation myocardial infarction (STEMI) treated with primary PCI
(PPCI) is not well established. Moreover, the optimal cutoff value for prediction of
mortality has never been determined.
Methods: Admission glucose levels were available in 3,405 pts enrolled in the
HORIZONS-AMI trial, of whom 566 (16.6%) had known diabetes mellitus. Outcomes
were stratified by baseline glucose level and diabetes status.
Results: Median [IQR] admission glucose level in the entire study cohort was 138
[115, 171] mg/dl, and was higher in pts with vs. without diabetes (206 [161, 247] vs.
131 [112, 156] mg/dl, P<0.0001). Hyperglycemia was strongly associated with
increased early and late mortality (Figure). By multivariable analysis, elevated
admission glucose level (upper tertile) was an independent predictor of 3-year mortality
in all pts (adjusted HR[95%CI] = 1.93 [1.35, 2.76], P=0.0003; diabetic pts (2.65 [1.28,
5.47], P=0.008); and non-diabetic pts (1.58 [1.05, 2.36], P=0.03). By ROC analysis,
the best cut-off values for 30-day mortality were 169 mg/dl for all pts (AUC=0.76),
149 mg/dl for non-diabetics (AUC=0.77), and 231 mg/dl for diabetics (AUC=0.69).
Time-to-event curves through 36 months for all-cause death in the entire cohort
Conclusion: In patients with STEMI undergoing primary PCI, baseline hyperglycemia
at the time of admission is an independent predictor of mortality in both diabetic and
non-diabetic pts. Even mildly elevated admission glucose levels are associated with
reduced survival in pts without known diabetes.
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The impact of BTK runoff score on the patency after stenting for SFA lesion
Ikki Komatsu, Toshiya Muramatsu, Reiko Tsukahara, Yoshiaki Ito, Tsuyoshi Sakai,
Hirhoshi Ishimori, Keisuke Hirano, Masatsugu Nakano, Masahirho Yamawaki,
Motoharu Araki, Tamon Katou, Hideyuki Takimura, Yasunari Sakamoto, Takurou
Takama
Cardiology, Saiseikai Yokohama-city Earstern Hospital, Yokohama, Kanagawa,
Japan
Background: After Endovascular treatment (EVT) for SFA lesions, the in flow of BTK
will increase. But very little is known about how the BTK flow or vascular resistance
of BTK has impact on the outcome of EVT after SFA lesions. Present study was aimed
to investigate the relationships between BTK flow and the patency after SFA stentings.
Methods: From April 2007 to June 2010, continuously 108 patients, 142 limbs who
deployed self expandable naitinor stent for SFA lesion at our institution were enrolled
in this study. The ‘BTK score’ was gave as the sum of following flow points; ‘good 0’,
’stenosis 1’, ’collateral 2’, ’poor 2.5’, ’occlude 3’ for each BTK artery (ATA,PA,PTA)
and pedal arch. From the result of Primary patency after SFA stenting, we divide
following two groups: Group NP; not patent, n=26 limbs, average BTK score 5.0±2.7
and Group P; patent, n=115 limbs, average BTK score 4.3±3.0. The patient, lesion,
technical backgrounds and clinical outcome were evaluated and compared. In addition,
the BTK score was divided in three following groups; Low 1-4/Intermediate 4-8/High
9-12. Results)
Results: Primly patency rate was 81% in this study setting. The patient backgrounds
were well matched include CLI limbs (Group NP: 4 limbs 17%,Group P: 39 limbs
33%,p=0.10) and Rutherford category 5 or 6 cases (Group NP: 2 limbs 8.7%, Group
P: 22 limbs 19%,p=0.36). TASK C, D limbs (Group NP: 18 limbs 78%>Group P: 64
limbs 55%,p=0.07) were tend to and CTO lesions (Group NP: 17 limbs 73%>Group
P: 63 limbs 54%,p=0.04) were seen significantly higher in group NP. No cardiac death
was seen in this study term. And no case of group NP and 2 cases of group P received
major amputation. The number of Low/Intermediate/High BTK score (1-4/ 4-8/ 9-12
points) in group NP vs. group P were as follow; Low; 10 limbs 43.5% vs. 64 limbs
55.6%,p=0.07,Intermediate; 10 limbs 43.5% vs. 42 limbs 36.5%,p=0.03,High;3 limbs
13% vs. 9 limbs 7.8%,p=0.03.
Conclusion: From this study, it can be concluded that the Primary stent patency after
EVT for SFA lesion is associated with the lesion severity and BTK runoff score
severity.
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